AstraZeneca will initially deliver fewer vaccines than expected. This is because a European production location (temporarily) cannot make as many vaccines as expected, the pharmaceutical company reported to NU.nl on Friday after reporting by Bild.
It is not yet clear exactly how large the deficit will be and how long the delay will last. A spokesperson cannot say whether it is only about the first quarter or first half of 2021.
Despite the setback, AstraZeneca announced its intention to supply tens of millions of doses to the European Union in February and March, “while continuing to increase production volumes”.
AstraZeneca made an official application last week to the European Medicines Agency (EMA) to approve the vaccine. The AstraZeneca vaccine, when approved, would be the third COVID-19 vaccine considered safe by EMA.
EMA hopes to reach a judgment (approval or no approval) next Friday. The Netherlands has an option for nearly twelve million doses, good for vaccinating nearly six million Dutch people. Together, the 27 European member states have an option for about four hundred million vaccines.